565 related articles for article (PubMed ID: 29375202)
1. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art.
Facciorusso A
World J Gastroenterol; 2018 Jan; 24(2):161-169. PubMed ID: 29375202
[TBL] [Abstract][Full Text] [Related]
2. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
3. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
[No Abstract] [Full Text] [Related]
4. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
5. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
6. A comparison between drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis of six randomized controlled trials.
Wang H; Cao C; Wei X; Shen K; Shu Y; Wan X; Sun J; Ren X; Dong Y; Liu Y; Zhai B
J Cancer Res Ther; 2020; 16(2):243-249. PubMed ID: 32474508
[TBL] [Abstract][Full Text] [Related]
7. Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size.
Lee YK; Jung KS; Kim DY; Choi JY; Kim BK; Kim SU; Park JY; Ahn SH; Han KH; Kim GM; Kim MD; Park SI; Won JY; Lee DY
J Gastroenterol Hepatol; 2017 Feb; 32(2):487-496. PubMed ID: 27503585
[TBL] [Abstract][Full Text] [Related]
8. DEB-TACE: a standard review.
Melchiorre F; Patella F; Pescatori L; Pesapane F; Fumarola E; Biondetti P; Brambillasca P; Monaco C; Ierardi AM; Franceschelli G; Carrafiello G
Future Oncol; 2018 Dec; 14(28):2969-2984. PubMed ID: 29987957
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis.
Zou JH; Zhang L; Ren ZG; Ye SL
J Dig Dis; 2016 Aug; 17(8):510-517. PubMed ID: 27384075
[TBL] [Abstract][Full Text] [Related]
10. Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review.
Yang B; Liang J; Qu Z; Yang F; Liao Z; Gou H
PLoS One; 2020; 15(2):e0227475. PubMed ID: 32074102
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma.
Cucchetti A; Trevisani F; Cappelli A; Mosconi C; Renzulli M; Pinna AD; Golfieri R
Dig Liver Dis; 2016 Jul; 48(7):798-805. PubMed ID: 27263056
[TBL] [Abstract][Full Text] [Related]
12. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
Tang J; Huang Z; Xu J; Lv Q; Wang P
Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
[TBL] [Abstract][Full Text] [Related]
13. Conventional
Song JE; Kim DY
World J Hepatol; 2017 Jun; 9(18):808-814. PubMed ID: 28706579
[TBL] [Abstract][Full Text] [Related]
14. Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula.
Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Hao Y; Zheng X; Li C; Li W
Cancer Biol Ther; 2022 Dec; 23(1):89-95. PubMed ID: 35230928
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
[TBL] [Abstract][Full Text] [Related]
16. Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future.
Woo HY; Heo J
Clin Mol Hepatol; 2015 Dec; 21(4):344-8. PubMed ID: 26770921
[TBL] [Abstract][Full Text] [Related]
17. Transcatheter arterial embolic therapies for hepatocellular carcinoma: a literature review.
Nishikawa H; Kita R; Kimura T; Osaki Y
Anticancer Res; 2014 Dec; 34(12):6877-86. PubMed ID: 25503113
[TBL] [Abstract][Full Text] [Related]
18. CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study.
Zhang X; Zhou J; Zhu DD; Huang J; Sun JH; Li TF; Shi CS; Sun ZC; Hou QM; Peng ZY; Yu WQ; Ji JS; Gu WJ; Zhou GH; Xie XX; Guo XH; Cao GH; Yu ZH; Xu HH; Fang J; Ying SH; Hu WH; Ji WB; Han J; Wu X; Zheng JP; Luo J; Chen YT; Hu TY; Li L; Hu HJ; Du HJ; Shao GL
Clin Transl Oncol; 2019 Feb; 21(2):167-177. PubMed ID: 30003530
[TBL] [Abstract][Full Text] [Related]
19. Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients.
Facciorusso A; Licinio R; Muscatiello N; Di Leo A; Barone M
World J Hepatol; 2015 Aug; 7(16):2009-19. PubMed ID: 26261690
[TBL] [Abstract][Full Text] [Related]
20. Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads.
Guiu B; Deschamps F; Aho S; Munck F; Dromain C; Boige V; Malka D; Leboulleux S; Ducreux M; Schlumberger M; Baudin E; de Baere T
J Hepatol; 2012 Mar; 56(3):609-17. PubMed ID: 22027582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]